Kymera Therapeutics KYMR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating income?
- Kymera Therapeutics (KYMR) reported operating income of -$84.15M in Q1 2026.
- How has Kymera Therapeutics's operating income changed year-over-year?
- Kymera Therapeutics's operating income decreased by 13.1% year-over-year, from -$74.43M to -$84.15M.
- What is the long-term trend for Kymera Therapeutics's operating income?
- Over 4 years (2021 to 2025), Kymera Therapeutics's operating income has grown at a 36.5% compound annual growth rate (CAGR), from -$100.53M to -$349.4M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.